Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PFE

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

Thirty-five generic drugmakers will produce low-cost versions of Pfizer Inc's (NYSE:PFE) COVID-19 pill, Paxlovid, to expand supplies of the highly effective drug in lower-income regions. Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries, covering up to approximately 53% of the…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Pfizer-BioNTech Seek FDA Approval For Second COVID-19 Booster In Elderly Population

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) filed an application with the

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer To Stop New Clinical Trials In Russia: Reuters

Reuters reported that Pfizer Inc (NYSE: PFE) said it wo

Benzinga

Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows

The Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.

Benzinga

Pfizer's Paxlovid Becomes First Oral COVID-19 Therapy To Be Evaluated In Pediatric Clinical Study

Pfizer Inc (NYSE: PFE) has initiated a Phase 2/3 EPIC-PEDS trial to evaluate Paxlovid (nirmatrelvir and ritonavir tablets)

Benzinga

Pfizer Commits 10M Courses Of COVID-19 Oral Antiviral To Developing Countries: Reuters

Pfizer Inc (NYSE:PFE) is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries in 2022, reports Reuters citing an official with the Global Fund. The Fund's head of strategy for policy, Harley Feldbaum, said Pfizer had committed at least that many…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows

According to a published study, Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) two-dose COVID-19 vaccine provided very little protection for children aged 5 to 11 years during the wave of o

Benzinga

Pfizer's Clostridioides Difficile Vaccine Fails To Prevent C. Difficile Infection

Pfizer Inc (NYSE: PFE) announced data from the CLOVER Phase 3 trial evaluating Clostridioides difficile vaccine candidate to prevent C. difficile infection (CDI).

Benzinga

5 High-Quality Mega-Cap Stocks to Scoop Up Now

In addition to inflationary pressure, economic sanctions imposed on Russia by various countries and corporations in response to Russia’s invasion of Ukraine have exacerbated volatility in the global markets. As investors seek to avoid that volatility and generate stable returns, we think high-quality mega-cap stocks Pfizer (PFE), Cisco (CSCO), Abbott…

StockNews.com

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga

Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process,

Benzinga

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

StockNews.com

Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Expert Ratings For Pfizer

Analysts have provided the following ratings for Pfizer (NYSE:PFE) within the last quarter:

Benzinga

Pfizer Q4 Sales Lag Consensus; Forecasts $54B In FY22 From COVID-19 Vaccine, Treatment Pill

Pfizer Inc (NYSE: PFE) has reported

Benzinga

5 Stocks To Watch For February 8, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Pfizer Inc. (NYSE: PFE) to report quarterly earnings at $0.87 per share on revenue of $24.20 billion before the opening bell. Pfizer shares rose 1.7% to $54.10 in after-hours trading.

Benzinga

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) have

Benzinga

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Benzinga

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Pharmaceutical Stocks to Buy for the Long-Term

The global pharmaceutical industry is expected to witness stable growth over the long term, owing to the rising medical needs of an aging population and consistent innovations in the treatment of chronic ailments. So, we think it could be wise to scoop up shares of quality pharmaceutical stocks Johnson &…

Benzinga

Pfizer's COVID-19 Oral Antiviral Shows In-Vitro Efficacy Against Omicron Variant

Pfizer Inc (NYSE: PFE) yesterday

1 … 10 11 12 13

Organisations

Centers for Disease Control and Prevention

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Omicron

2,972 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.